Skip to main content
. 2022 Dec 15;11(24):7429. doi: 10.3390/jcm11247429

Table 1.

Timeline of interventions and outcomes.

Timeline Medical History and Past Interventions
2019 Diagnosis of asthma and chronic sinusitis
Antibiotic treatment for recurrent respiratory infections
Diagnostic testing and interventions
July 2020 Onset of symptoms
  • -

    Hospitalization due to weakness, persistent low-grade fever, and cough

  • -

    Lab tests: eosinophils 12,170 cells/mL, 34%; Hgb: 9.7 mg/dL; leukocytes 21,660 cells/mL; ESR 120 mm/h; CRP 78,100 µg/L; polyclonal hypergammaglobulinemia 32%; total serum IgE 672 IU/mL; and proteinuria 50 mg/dL

  • -

    BMB (August 2020): FISH for PDGFRα, FIP1L1, CHIC2 rearrangements negative
September 2020 Diagnosis of EGPA
  • -

    Dermatology consultation for widespread cutaneous lesions

  • -

    Skin biopsy: eosinophilic necrotizing vasculitis

  • -

    Lab tests: MPO-ANCA 48 IU/mL
September 2020 Baseline assessment
  • -

    BVAS 24

  • -

    CT scan: pulmonary diffuse ground glass opacities and apical pseudo-nodular lesions; inflammatory thickening and erosion of paranasal sinuses

  • -

    Cardiac MRI: eosinophilic myocarditis in the chronic phase

  • -

    ENG: initial sensory-motor polyneuropathy
October 2020 Start of treatment
  • -

    Methylprednisolone 30 mg/day IV

  • -

    Rituximab 375 mg/m2 IV once-a-week for four weeks

  • -

    Methylprednisolone de-escalation to 8 mg/day (November 2020)
January 2021 Remission (10-week follow-up)
  • -

    BVAS 5

  • -

    Lab tests: hypogammaglobulinemia 9%, ANCA negative, proteinuria negative
Maintenance
  • -

    Rituximab 500 mg IV every 6 months

  • -

    Methylprednisolone 2 mg/day

Abbreviations: BMB, bone marrow biopsy; BVAS, Birmingham Vasculitis Activity Score; CHIC2, cysteine rich hydrophobic domain 2; CRP, C-reactive protein; CT, computerized tomography; EGPA, eosinophilic granulomatosis with polyangiitis; ENG, electroneurography; ESR, erythrocyte sedimentation rate; FIP1L1, factor interacting with PAPOLA and CPSF1; FISH, fluorescence in situ hybridization; Hgb, hemoglobin; IgE, immunoglobulin E; IV, intravenously; MPO-ANCA, anti-myeloperoxidase anti-neutrophil cytoplasmic antibodies; MRI, magnetic resonance imaging; PDGFRα; platelet-derived growth factor receptor.